Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs GroupVRAX -4.08%45 Debt-to-Equity is 0.06 as of Mar. 2026, which is 20% above its 10-year median of 0.05. GuruFocus rates VRAX with a GF Score™ of 45/100 and a GF Value™ of $3.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Biotechnology companies, Virax Biolabs Group ranks better than 68.38% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Virax Biolabs Group's Debt-to-Equity or its related term are showing as below:
VRAX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.07
Current: 0.06
During the past 7 years, the highest Debt-to-Equity Ratio of Virax Biolabs Group was 0.07. The lowest was 0.02. And the median was 0.05.
VRAX's Debt-to-Equity is ranked better than 68.38% of 955
companies
in the Biotechnology industry
Industry Median: 0.16
vs VRAX: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Virax Biolabs Group Debt-to-Equity Related Terms
Virax Biolabs Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs ISCO, PKTX, GRI: Debt-to-Equity Comparison
For the Biotechnology subindustry, Virax Biolabs Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Debt-to-Equity of 0.06 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Virax Biolabs Group and its competitors. This is 20% above median its historical median of 0.05. Over the past decade, Virax Biolabs Group's Debt-to-Equity has ranged from 0.02 to 0.07. According to the industry distribution chart, Virax Biolabs Group ranks #302 out of 955 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Virax Biolabs Group's Debt-to-Equity too high?
Virax Biolabs Group's current Debt-to-Equity of 0.06 is 20% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.07. The Biotechnology industry median Debt-to-Equity is 0.16. Virax Biolabs Group's value of 0.06 is 62.5% below this industry median. Based on the distribution chart, Virax Biolabs Group ranks #302 out of 955 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Debt-to-Equity compare to ISCO and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #302 out of 955 companies for Debt-to-Equity. This puts Virax Biolabs Group in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Virax Biolabs Group's value of 0.06 is 62.5% below this benchmark. Historically, Virax Biolabs Group's own Debt-to-Equity has ranged from 0.02 to 0.07 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.16, Virax Biolabs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Debt-to-Equity is 0.06, which is 20% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.56, compared to a current price of $2.82 — trading 20.8% below its estimated fair value. The current Debt-to-Equity is 0.06, which is 20% above median its 10-year median of 0.05 and 62.5% below the Biotechnology industry median of 0.16. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Debt-to-Equity is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $2.82 is trading 20.8% below its estimated GF Value™ of $3.56.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
Debt-to-Equity: 0.06 (20% above median its 10-year median of 0.05)
GF Value™: $3.56 vs. price of $2.82 (20.8% below fair value)
Industry Position: 62.5% below the Biotechnology median (#302 of 955)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
